查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1519529

2024-2032 年按治療類型、疾病類型（肝炎、自體免疫疾病、非酒精性脂肪肝、癌症、遺傳性疾病等）、最終用戶和地區分類的肝病治療市場報告

Liver Disease Treatment Market Report by Treatment Type, Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others), End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2023年全球肝病治療市場規模達238億IMARC Group。

肝臟是人體的重要器官，具有重要的功能，例如儲存維生素和營養物質、清除血液中的有害物質以及維持體內化學物質的適當平衡。癌症、肝炎、自體免疫疾病和遺傳性疾病是一些常見的肝臟疾病。這些疾病通常由感染、遺傳、肥胖、糖尿病和免疫系統異常引起。一些廣泛使用的肝病治療技術包括疫苗、化療、抗病毒藥物、免疫球蛋白、皮質類固醇和免疫抑制劑。肝病治療有助於膽固醇和荷爾蒙的排泄，增加膽汁的產生和酵素的活化。

肝病治療市場趨勢：

全球老年人口不斷增加，容易患各種慢性疾病，包括肝病，這是推動市場成長的主要因素之一。飲食模式的變化和久坐的生活方式正在推動市場成長。此外，由於高膽固醇、肥胖、高血壓和糖尿病導致的脂肪肝疾病的盛行率不斷增加，有利於市場的成長。此外，各種技術進步，例如生物人工肝的發展，正在為市場成長提供動力。它利用再生肝細胞取代肝功能，廣泛用於急性肝衰竭患者。與此一致的是，抗病毒藥物的迅速採用，因為它們安全有效，有助於抑制乙型肝炎病毒，並有助於降低肝硬化和肝細胞癌的風險，對市場成長產生積極影響。除此之外，不斷增加的研發（R＆D）活動、醫療保健行業的顯著成長以及政府促進公共衛生的各種舉措的實施正在為市場創造積極的前景。

本報告回答的關鍵問題

  • 2023年全球肝病治療市場規模有多大？
  • 2024-2032年全球肝病治療市場的預期成長率是多少？
  • 推動全球肝病治療市場的關鍵因素是什麼？
  • COVID-19 對全球肝病治療市場有何影響？
  • 根據治療類型，全球肝病治療市場的細分如何？
  • 根據疾病類型，全球肝病治療市場的細分如何？
  • 基於最終用戶的全球肝病治療市場的詳細情形如何？
  • 全球肝病治療市場的重點區域有哪些？
  • 全球肝病治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球肝病治療市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依治療類型

  • 抗病毒藥物
    • 市場走向
    • 市場預測
  • 免疫抑制劑
    • 市場走向
    • 市場預測
  • 疫苗
    • 市場走向
    • 市場預測
  • 免疫球蛋白
    • 市場走向
    • 市場預測
  • 皮質類固醇
    • 市場走向
    • 市場預測
  • 標靶治療
    • 市場走向
    • 市場預測
  • 化療
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依疾病類型

  • 肝炎
    • 市場走向
    • 市場預測
  • 自體免疫疾病
    • 市場走向
    • 市場預測
  • 非酒精性脂肪肝（NAFLD）
    • 市場走向
    • 市場預測
  • 癌症
    • 市場走向
    • 市場預測
  • 遺傳性疾病
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 門診手術中心
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
Product Code: SR112024A5023

The global liver disease treatment market size reached US$ 23.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.

The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.

Liver Disease Treatment Market Trends:

The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global liver disease treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on treatment type, disease type and end user.

Breakup by Treatment Type:

Antiviral Drugs

Immunosuppressants

Vaccines

Immunoglobulins

Corticosteroids

Targeted Therapy

Chemotherapy

Breakup by Disease Type:

Hepatitis

Autoimmune Diseases

Non-alcoholic Fatty Liver Disease (NAFLD)

Cancer

Genetic Disorders

Others

Breakup by End User:

Hospitals

Ambulatory Surgical Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global liver disease treatment market in 2023?
  • 2. What is the expected growth rate of the global liver disease treatment market during 2024-2032?
  • 3. What are the key factors driving the global liver disease treatment market?
  • 4. What has been the impact of COVID-19 on the global liver disease treatment market?
  • 5. What is the breakup of the global liver disease treatment market based on the treatment type?
  • 6. What is the breakup of the global liver disease treatment market based on the disease type?
  • 7. What is the breakup of the global liver disease treatment market based on the end user?
  • 8. What are the key regions in the global liver disease treatment market?
  • 9. Who are the key players/companies in the global liver disease treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Liver Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Antiviral Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Vaccines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunoglobulins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Corticosteroids
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Targeted Therapy
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Chemotherapy
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Hepatitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Non-alcoholic Fatty Liver Disease (NAFLD)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Genetic Disorders
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AbbVie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Astellas Pharma Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Emergent BioSolutions Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Gilead Sciences Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 GlaxoSmithKline plc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck & Co. Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novartis AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Sanofi S.A.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis
    • 14.3.14 Takeda Pharmaceutical Company Limited
      • 14.3.14.1 Company Overview
      • 14.3.14.2 Product Portfolio
      • 14.3.14.3 Financials
      • 14.3.14.4 SWOT Analysis
    • 14.3.15 Viatris Inc.
      • 14.3.15.1 Company Overview
      • 14.3.15.2 Product Portfolio
      • 14.3.15.3 Financials

List of Figures

  • Figure 1: Global: Liver Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Liver Disease Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Liver Disease Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Liver Disease Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 5: Global: Liver Disease Treatment Market: Breakup by Disease Type (in %), 2023
  • Figure 6: Global: Liver Disease Treatment Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Liver Disease Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Liver Disease Treatment (Antiviral Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Liver Disease Treatment (Antiviral Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Liver Disease Treatment (Immunosuppressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Liver Disease Treatment (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Liver Disease Treatment (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Liver Disease Treatment (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Liver Disease Treatment (Immunoglobulins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Liver Disease Treatment (Immunoglobulins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Liver Disease Treatment (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Liver Disease Treatment (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Liver Disease Treatment (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Liver Disease Treatment (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Liver Disease Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Liver Disease Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Liver Disease Treatment (Hepatitis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Liver Disease Treatment (Hepatitis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Liver Disease Treatment (Autoimmune Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Liver Disease Treatment (Autoimmune Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Liver Disease Treatment (Non-alcoholic Fatty Liver Disease (NAFLD)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Liver Disease Treatment (Non-alcoholic Fatty Liver Disease (NAFLD)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Liver Disease Treatment (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Liver Disease Treatment (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Liver Disease Treatment (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Liver Disease Treatment (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Liver Disease Treatment (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Liver Disease Treatment (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Liver Disease Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Liver Disease Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Liver Disease Treatment (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Liver Disease Treatment (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Liver Disease Treatment (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Liver Disease Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: North America: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: North America: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United States: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United States: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Canada: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Canada: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Asia-Pacific: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Asia-Pacific: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: China: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: China: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Japan: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Japan: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: India: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: India: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: South Korea: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: South Korea: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Australia: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Australia: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Indonesia: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Indonesia: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Europe: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Europe: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Germany: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Germany: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: France: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: France: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: United Kingdom: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: United Kingdom: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Italy: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Italy: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Spain: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Spain: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Russia: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Russia: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Latin America: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Latin America: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Brazil: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Brazil: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Mexico: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Mexico: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Others: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Middle East and Africa: Liver Disease Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Middle East and Africa: Liver Disease Treatment Market: Breakup by Country (in %), 2023
  • Figure 88: Middle East and Africa: Liver Disease Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Global: Liver Disease Treatment Industry: SWOT Analysis
  • Figure 90: Global: Liver Disease Treatment Industry: Value Chain Analysis
  • Figure 91: Global: Liver Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Liver Disease Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Liver Disease Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Liver Disease Treatment Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Liver Disease Treatment Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Liver Disease Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Liver Disease Treatment Market: Competitive Structure
  • Table 7: Global: Liver Disease Treatment Market: Key Players